Abstract:4542 Background: Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to ICI by reducing immune-suppressive myeloid cells in metastatic ccRCC (Msaouel, Sci Transl Med 2022). ICI is the standard first-line (1L) treatment of metastatic ccRCC, and there is unmet need for improved treatment outcomes after progression on ICI. We hypothesized that sitravatinib plus nivolumab would revert an immunosuppressive tumor microenvironment (TME) to improve objective response rate (ORR) and survival in patients with metastatic ccRCC whose disease progressed on or after ICI. Methods: In this investigator-initiated, phase II, multicenter trial (NCT04904302), patients with progressive metastatic ccRCC after 1-2 lines of treatment were enrolled into three cohorts: Cohort A) progression on 1L nivolumab + ipilimumab, Cohort B) progression on 1L pembrolizumab + axitinib or 2L anti-PD-1 therapy after receiving 1L VEGF-targeted monotherapy, Cohort C) progression on 1L or 2L cabozantinib or lenvatinib +/- everolimus either before, after, or in combination with anti-PD-1 ICI. Starting dose of sitravatinib was 100 mg PO daily and nivolumab was 480 mg IV every 4 weeks. The co-primary endpoints were ORR [complete response (CR) + partial response (PR)] and disease control rate [DCR; CR, PR or stable disease (SD) at 24 weeks]. The study was designed to enroll 88 patients with an interim analysis for futility in each cohort using a BOP2 design, but it was terminated early due to discontinuation of sitravatinib development by the sponsor. Results: 14 patients were enrolled with 2 in cohort A, 6 in cohort B and 6 in cohort C. Most patients had IMDC intermediate risk disease (n=11, 78.6%), 7 patients had prior nephrectomy (50%), and sarcomatoid dedifferentiation was present in the tumors of 2 patients (7.1%). Across all cohorts, the ORR was 15.4% (2/13, 1 patient not evaluable) and DCR at 24 weeks was 35.7% (5/14). The 2 patients who experienced a PR were pre-treated with nivolumab + ipilimumab and pembrolizumab + axitinib. DCR at 24 months was 63% for Cohort A+B and 0% for Cohort C. After a median follow up of 11.9 months (mo), 10 patients had discontinued treatment (71.4%), all due to disease progression, and 6 patients had died (42.9%). Median progression free survival was 5.5 mo [ 95% CI 3.8 – not reached (NR)], and median overall survival was 13.3 mo (95% CI 8.77 – NR). Six patients (42.9%) experienced a grade 3-4 adverse event (AE) and 2 patients (14.3%) experienced an immune-mediated AE. Conclusions: In this small phase 2 trial with limited sample size due to early termination, sitravatinib plus nivolumab demonstrated a manageable safety profile and produced modest clinical benefit. The observed responses occurred in patients who did not receive prior treatment with cabozantinib or lenvatinib. Clinical trial information: NCT04904302 .

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

Sunitinib in Treatment of Advanced Non-Small Cell Lung Cancer after Failure of Multiregimens of Chemotherapy and Egfr-Tki

Sunitinib in Patients with Refractory NSCLC: Primary Results from China.

Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer

Sunitinib in Pretreated Advanced Non-Small-cell Lung Carcinoma: a Primary Result from Asian Population

Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study

Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)

Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

Chemotherapy with or Without Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer: A Randomized, Placebo Controlled Phase II Study CALGB 30504 (ALLIANCE).

A Phase II Trial of Sitravatinib Plus Nivolumab after Progression on Prior Immune Checkpoint Inhibitor (ICI) in Patients with Metastatic Clear Cell Renal Cell Carcinoma (Ccrcc).

The Evaluation of Efficacy and Safety of Sunitinib on EGFR‐TKI Pretreated Advanced Non‐small Cell Lung Cancer Patients in China

P3.02c-025 Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer

Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial

P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy As 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

The Efficacy and Safety of Sunitinib in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors.

Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours

Phase Ib/IIa Study Assessing the Safety and Efficacy of AL8326 Monotherapy in Patients with ≥3rd Line Small Cell Lung Cancer (SCLC) Treatment.

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours